IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
Pasquale L Fedele, Simon N Willis, Yang Liao, Michael S Low, Jai Rautela, David H Segal, Jia-Nan Gong, Nicholas D Huntington, Wei Shi, David CS Huang, George Grigoriadis, Julie Tellier, Stephen L Nutt
Blood | AMER SOC HEMATOLOGY | Published : 2018
Awarded by National Health and Medical Research Council (NHMRC) Australia
Awarded by NHMRC Australia
Awarded by Royal Australasian College of Physicians
Awarded by Leukemia and Lymphoma Society Specialized Center of Research Grant
This project was supported by research grants from the National Health and Medical Research Council (NHMRC) Australia (1054618 and 1058238 to S.L.N, 1016701 to D.C.S.H.). The study was partly funded by the Cancer Council Victoria's Grant-in-Aid Scheme (to S.L.N.). P.L.F. was supported by a Leukaemia Foundation of Australia Clinical Scholarship and a Royal College of Pathologists of Australasia Foundation Postgraduate Research Fellowship, S.N.W. by The Walter and Eliza Hall Trust Centenary Fellowship, M.S.L. by a CRB Blackburn scholarship (GNT1075151) jointly from the NHMRC Australia and Royal Australasian College of Physicians, W.S. was supported by a Walter and Eliza Hall Centenary Fellowship sponsored by Commonwealth Serum Laboratories Limited, and D.C.S.H. by an NHMRC Australia fellowship and funding from the Leukemia and Lymphoma Society Specialized Center of Research Grant (7001-13). This work was made possible through Victorian State Government Operational Infrastructure Support and NHMRC Independent Research Institute Infrastructure Support Scheme.